Anuh Pharma (506260) Q4 25/26 earnings summary

Executive summary

• Audited financial results for the quarter and year ended 31 March 2026 were approved, with an unmodified audit opinion from statutory auditors.

• A final dividend of ₹1.50 per equity share (30% payout) was recommended, subject to shareholder approval.

• Key board decisions included re-appointments of directors, appointment of a new General Manager - Quality, and adoption of revised MOA and AOA.

• Requests for reclassification of certain promoter group shareholders to public category were received.

Financial highlights

• Revenue from operations for FY26 was ₹77,165.74 lakh, up from ₹66,151.49 lakh in FY25.

• Net profit after tax for FY26 was ₹4,104.61 lakh, compared to ₹4,735.19 lakh in FY25.

• EBITDA for FY26 was ₹6,607.59 lakh (margin 8.56%), down from ₹7,036.40 lakh (margin 10.64%) in FY25.

• EPS for FY26 was ₹4.10, compared to ₹4.72 in FY25.

• Other income for Q4 FY26 included a mark-to-market loss on investments of ₹189.77 lakh.

Outlook and guidance

• Dividend payout and board decisions are subject to shareholder approval at the upcoming AGM.

• The company assessed the impact of new labor codes, resulting in increased gratuity and leave liabilities.